ArticleKidney international reports2026
Mortality and Practice Patterns in the MEXHEMO Hemodialysis Cohort.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic kidney disease represents a major public health challenge in Mexico. In the absence of a national hemodialysis (HD) registry, epidemiological data on patient characteristics, treatment practices, and outcomes remain scarce. The MEXHEMO project aims to characterize the clinical profile and outcomes of Mexican patients undergoing chronic HD. Methods: This was a retrospective, observational cohort study. Centers nationwide were invited to report data from patients receiving maintenance HD between January 1 and June 30, 2023. Demographic, clinical, dialysis-related, and laboratory information was collected. Vital status was ascertained from medical records at each dialysis center, with 6 months of follow-up. Outcomes were mortality rates, standardized mortality ratios (SMRs), and risk factors for death. SMRs were calculated using the 2019 United States Renal Data System (USRDS) and the 2024 Chilean HD registry as reference populations. Results: A total of 11,779 patients from 41 clinics were included. Mean age was 52 ± 16 years; 57% were male, and 92% had social security coverage. High-flux HD was prescribed in 86%, and 43% underwent dialyzer reuse. The crude mortality rate was 130 (95% confidence interval [CI]: 121-139) deaths/1000 patient-yrs. SMR were 1.31 (95% CI: 1.25-1.38) compared with the USRDS, and 1.57 (95% CI: 1.52-1.62) compared with the Chilean registry. Lack of social security coverage, hypoalbuminemia, hemoglobin (Hb) ≤ 9 g/dl, catheter use, and dialyzer reuse were independently associated with mortality. Conclusion: MEXHEMO constitutes the largest cohort of HD patients reported in Mexico. The findings highlight elevated mortality despite a relatively young population, emphasizing the need for a national registry and quality improvement policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.